BRKR

Bruker is a developer of high-performance scientific instruments and analytical/diagnostic systems across four segments (BioSpin, CALID, NANO, BEST). FY2025 was a clear step backward. Revenue rose only 2.1% to $3.44B, but the quality of that growth was poor: management's own non-GAAP organic revenue fell 3.7% and constant-currency revenue was -0.2%, meaning the headline growth came from acquisitions and currency, not the underlying business. Profitability deteriorated sharply — GAAP operating income collapsed 73.1% to $68.2M (a 2.0% margin versus 7.5% in 2024), gross margin fell to 45.9% from 49.0%, and the company swung to a net loss of -$8.60M (EPS -$0.15). Operating cash flow nearly halved to $134M.

The MD&A frames the gap as transitory acquisition, integration, IT-transformation and restructuring costs — on a non-GAAP basis operating margin was 12.6% and the franchise still generated positive (if thin) free cash flow of $43.3M. There are also some balance-sheet positives: equity rose 37.9% to $2.46B (partly from a 10.2% increase in shares), long-term debt fell 10.2% to $1.85B, and cash grew to $299M, lowering liabilities/equity to 1.52x. Management cites a long list of headwinds — soft academic/research budgets, tariffs, the China-US tensions affecting its supply chain, and FX — as drivers of the quarterly volatility.